S. Murray Sherman to Cost-Benefit Analysis
This is a "connection" page, showing publications S. Murray Sherman has written about Cost-Benefit Analysis.
Connection Strength
0.172
-
Cost-effectiveness of real-world administration of tobacco pharmacotherapy in the United States Veterans Health Administration. Addiction. 2019 08; 114(8):1436-1445.
Score: 0.119
-
The cost, survival, and quality-of-life implications of guideline-discordant imaging for prostate cancer. Cancer Rep (Hoboken). 2022 02; 5(2):e1468.
Score: 0.034
-
Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. Am J Gastroenterol. 2013 Mar; 108(3):410-5.
Score: 0.019